Tier 4 — mechanistic

Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin

Natasha Nayak Kolomeyer
ClinicalTrials.gov trial registry record 2021

Bibliography

Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Sponsor: Wills Eye Hospital. The proprietary supplement became unavailable after the producing company was acquired and production was discontinued.
Competing interests
No manuscript-level conflict-of-interest statement is available from the registry record.

Study snapshot

DesignProspective randomized placebo-controlled trial.
ModelAdults with primary open-angle glaucoma and visual-field loss.
Sample12 participants actually enrolled; 100 were originally planned.
InterventionGlaucoCetin, a proprietary multi-component medical food containing fisetin among other ingredients, taken as six capsules per day for six months, versus placebo. Fisetin dose was not reported.
DurationPlanned 6 months; trial terminated early.
EndpointsVisual field mean deviation; Visual function; Vision-related outcomes

What the study showed, in plain terms

GlaucoCetin was a randomized placebo-controlled glaucoma study of a proprietary medical food that included fisetin among several ingredients. Only 12 participants were enrolled before the trial was terminated after the supplement manufacturer was acquired and production stopped.

Because the intervention was multi-component, the fisetin dose was not reported, and the trial ended early, it cannot establish a fisetin effect on glaucoma or vision.

Key findings

  • Actual enrollment was 12 participants.
  • The intervention was GlaucoCetin, not purified fisetin.
  • The trial was terminated after product production was discontinued.

What this study can and cannot tell us

  • Terminated early with very small enrollment.
  • Multi-component product prevents fisetin-specific attribution.
  • Fisetin dose not reported.
  • No adequate efficacy conclusion can be drawn.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology